Drug Trial Radar · NCT01909934
Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
Last checked: Nov 20, 2026Latest source record: Sep 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
50
Actual
Start
Jan 23, 2014
Primary completion
May 4, 2021
Study completion Aug 29, 2024
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- Collaborators
- Takeda Development Center Americas, Inc.
- First posted
- Jul 29, 2013
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the antitumor efficacy of single-agent brentuximab vedotin 1.8 mg/kg administered intravenously (IV) every 3 weeks, as measured by the overall objective response rate (ORR) in patients with r/r sALCL following at least 1 multiagent chemotherapy regimen (cyclophosphamide, doxorubicin hydrochloride \[hydroxydaunorubicin\], vincristine sulfate \[Oncovin\], and prednisone \[CHOP\] or equivalent multiagent chemotherapy regimens with curative intent).
Conditions
- Lymphoma
Interventions
Brentuximab vedotinDrug
Brentuximab vedotin IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR)Time frame: Up to data cut-off date: 04 May 2021 (Up to approximately 7 years)
Locations
40 sites in 10 countries. Site status is shown where the registry gives one.
ZNA Stuivenberg
Antwerp, Belgium
Cliniques Universitaires Saint-Luc
Brussels, Belgium
Universitair Ziekenhuis Gent
Ghent, Belgium
UZ Leuven
Leuven, Belgium
Clinical Hospital Centre Rijeka
Rijeka, Croatia
Clinical Hospital Centre Zagreb
Zagreb, Croatia
Clinical Hospital Dubrava
Zagreb, Croatia
Fakultni nemocnice Brno
Brno, Czechia
Fakultni nemocnice Olomouc
Olomouc, Czechia
Fakultni nemocnice Kralovske Vinohrady
Prague, Czechia
Vseobecna fakultni nemocnice v Praze
Prague, Czechia
Semmelweis Egyetem
Budapest, Hungary
Debreceni Egyetem Klinikai Kozpont
Debrecen, Hungary
Pecsi Tudomanyegyetem
Pécs, Hungary
Uniwersyteckie Centrum Kliniczne
Gdansk, Poland
Malopolskie Centrum Medyczne s.c.
Krakow, Poland
SPZOZ MSW zWarminsko-MazurskimCen.Onko.wOlsztynie
Olsztyn, Poland
Centrum Onkologii-Instytut im. M. Sklodowskiej Curie
Warsaw, Poland
Hospital de Braga
Braga, Portugal
Centro Hospitalar de Lisboa Norte, E.P.E. - Hospital de Santa Maria
Lisbon, Portugal
Centro Hospitalar do Porto, E.P.E. - Hospital de Santo Antonio
Porto, Portugal
Instituto Portugues de Oncologia do Porto Francisco Gentil, EPE
Porto, Portugal
Policlinica de Diagnostic Rapid SA
Brasov, Romania
Spitalul Clinic Colentina
Bucharest, Romania
Spitalul Clinic Coltea
Bucharest, Romania
Spitalul Clinic Judetean de Urgenta Targu Mures
Târgu Mureş, Romania
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Hospital Universitario Ramon y Cajal
Madrid, Spain
Hospital Universitario de Salamanca
Salamanca, Spain
ICO lHospitalet Hospital Duran i Reynals
L'Hospitalet de Llobregat, Barcelona, Spain
Hospital Universitario Marques de Valdecilla
Santander, Cantabria, Spain
Ankara University Medical Faculty
Ankara, Turkey (Türkiye)
Pamukkale Uni. Med. Fac.
Denizli, Turkey (Türkiye)
Istanbul Bilim University Medical Fac.
Istanbul, Turkey (Türkiye)
Ege University Medical Faculty
Izmir, Turkey (Türkiye)
Dokuz Eylul University Faculty of Medicine
Izmir, Turkey (Türkiye)
Erciyes University Medical Faculty
Kayseri, Turkey (Türkiye)
Royal Cornwall Hospital
Truro, Cornwall, United Kingdom
The Christie
Manchester, Greater Manchester, United Kingdom
Birmingham Heartlands Hospital
Birmingham, West Midlands, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.